LT3135301T - Optimizuota in vivo įvedimo sistema su nukleorūgščių konjugatų endosomas lizuojančiais agentais - Google Patents

Optimizuota in vivo įvedimo sistema su nukleorūgščių konjugatų endosomas lizuojančiais agentais

Info

Publication number: LT3135301T
Authority: LT; Lithuania
Prior art keywords: optimized; nucleic acid; delivery system; vivo delivery; acid conjugates
Prior art date: 2010-06-22

Application number

LTEP16183451.0T

Other languages

English (en)

Inventor

Jian-Sheng Sun

Marie Dutreix

Maria QUANZ-SCHOEFFEL

Original Assignee

Onxeo

Institut Curie

Centre National De La Recherche Scientifique

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-06-22

Filing date

2011-06-21

Publication date

2018-07-10

2011-06-21 Application filed by Onxeo, Institut Curie, Centre National De La Recherche Scientifique filed Critical Onxeo

2018-07-10 Publication of LT3135301T publication Critical patent/LT3135301T/lt

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Biophysics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Botany (AREA)
Wood Science & Technology (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Zoology (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

LTEP16183451.0T 2010-06-22 2011-06-21 Optimizuota in vivo įvedimo sistema su nukleorūgščių konjugatų endosomas lizuojančiais agentais LT3135301T (lt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP10166936		2010-06-22

Publications (1)

Publication Number	Publication Date
LT3135301T true LT3135301T (lt)	2018-07-10

Family

ID=42727428

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LTEP16183451.0T LT3135301T (lt)	2010-06-22	2011-06-21	Optimizuota in vivo įvedimo sistema su nukleorūgščių konjugatų endosomas lizuojančiais agentais

Country Status (20)

Country	Link
US (5)	US9205099B2 (lt)
EP (4)	EP2585113A1 (lt)
JP (1)	JP5860874B2 (lt)
CN (2)	CN104788523B (lt)
AU (1)	AU2011269041B2 (lt)
CA (1)	CA2802463C (lt)
CY (1)	CY1120560T1 (lt)
DK (2)	DK3135301T3 (lt)
EA (2)	EA032867B9 (lt)
ES (2)	ES2784793T3 (lt)
HR (1)	HRP20180934T1 (lt)
HU (1)	HUE037926T2 (lt)
IL (2)	IL223467A (lt)
LT (1)	LT3135301T (lt)
PL (1)	PL3135301T3 (lt)
PT (1)	PT3135301T (lt)
RS (1)	RS57439B1 (lt)
SI (1)	SI3135301T1 (lt)
TR (1)	TR201807294T4 (lt)
WO (1)	WO2011161075A1 (lt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RS57439B1 (sr) *	2010-06-22	2018-09-28	Onxeo	Optimizovani sistem sa endosomolitičkim agensima za in vivo primenu konjugata nukleinskih kiselina
EP2527440A1 (en) *	2011-05-27	2012-11-28	Institut Curie	Cancer treatment by combining DNA molecules mimicking double strand breaks with hyperthermia
CN103550783A (zh) *	2013-04-27	2014-02-05	中国人民解放军军事医学科学院放射与辐射医学研究所	一种核酸类药物靶向递送***及其制备方法
PL3325623T6 (pl)	2015-07-23	2022-05-30	Institut Curie	Zastosowanie skojarzenia cząsteczki dbait i inhibitorów parp do leczenia nowotworu
WO2017053995A1 (en) *	2015-09-25	2017-03-30	Ionis Pharmaceuticals, Inc.	Conjugated antisense compounds and their use
CA3016355A1 (en) *	2016-03-01	2017-09-08	Onxeo	Treatment of cancer by systemic administration of dbait molecules
WO2017186882A1 (en)	2016-04-29	2017-11-02	Onxeo	A method of predicting a response to an anti-tumor treatment by means of signal interfering dna molecules
CN117919431A (zh) *	2016-12-01	2024-04-26	国立大学法人埼玉大学	药物递送***用胞吞作用增强剂及其制备方法
EP3570814B1 (en)	2017-01-19	2023-11-29	Universiteit Gent	Molecular adjuvants for enhanced cytosolic delivery of active agents
WO2018162439A1 (en)	2017-03-08	2018-09-13	Onxeo	New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
WO2018175445A1 (en) *	2017-03-20	2018-09-27	Northwestern University	Poly(lactic-co-glycolic acid) (plga) spherical nucleic acids
EP3461488A1 (en)	2017-09-27	2019-04-03	Onxeo	Combination of a dbait molecule and a hdac inhibitor for treating cancer
EP3765613A1 (en)	2018-03-13	2021-01-20	Onxeo	A dbait molecule against acquired resistance in the treatment of cancer
AU2019370892B2 (en) *	2018-11-01	2023-04-27	Alpha Tau Medical Ltd.	Intratumoral alpha-emitter radiation and activation of cytoplasmatic sensors for intracellular pathogen
US20220054524A1 (en) *	2018-12-21	2022-02-24	Onxeo	New conjugated nucleic acid molecules and their uses
MA55219A (fr) *	2019-03-06	2022-01-12	Generation Bio Co	Nanoparticules lipidiques non actives avec adn dépourvu de capside, non viral
EP3942045A1 (en)	2019-03-21	2022-01-26	Onxeo	A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2021148581A1 (en)	2020-01-22	2021-07-29	Onxeo	Novel dbait molecule and its use
TW202210633A (zh)	2020-06-05	2022-03-16	法商昂席歐公司	用於治療癌症之dbait分子與kras抑制劑的組合
TW202214857A (zh)	2020-06-19	2022-04-16	法商昂席歐公司	新型結合核酸分子及其用途
AU2022409713A1 (en)	2021-12-16	2024-06-20	Valerio Therapeutics	New conjugated nucleic acid molecules and their uses
WO2024119101A1 (en) *	2022-12-01	2024-06-06	Yale University	Stimuli-responsive traceless engineering platform for intracellular payload delivery

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU7759291A (en) *	1990-03-29	1991-10-21	Gilead Sciences, Inc.	Oligonucleotide-transport agent disulfide conjugates
US5843643A (en) *	1992-02-21	1998-12-01	Ratner; Paul L.	Site-specific transfection of eukaryotic cells using polypeptide-linked recombinant nucleic acid
US5646042A (en) *	1992-08-26	1997-07-08	Ribozyme Pharmaceuticals, Inc.	C-myb targeted ribozymes
DE4418965A1 (de) *	1994-05-31	1995-12-07	Boehringer Ingelheim Int	Verfahren zum Einbringen von Nukleinsäure in höhere eukaryotische Zellen
WO1995035287A1 (en)	1994-06-17	1995-12-28	F.Hoffmann-La Roche Ag	N,n'-bis(quinolin-4-yl)-diamine derivatives, their preparation and their use as antimalarials
FR2722506B1 (fr)	1994-07-13	1996-08-14	Rhone Poulenc Rorer Sa	Composition contenant des acides nucleiques, preparation et utilisations
WO1996041606A2 (en)	1995-06-08	1996-12-27	Therexsys Limited	Improved pharmaceutical compositions for gene therapy
AUPN741696A0 (en)	1996-01-05	1996-01-25	Commonwealth Scientific And Industrial Research Organisation	Delivery of nucleic acids ii
ES2279580T3 (es) *	1997-09-15	2007-08-16	Genetic Immunity, Llc	Composiciones para administrar genes a celulas de la piel que presentan antigenos.
WO2002085908A1 (en)	2001-04-24	2002-10-31	Purdue Research Foundation	Folate mimetics and folate-receptor binding conjugates thereof
DE10310196A1 (de)	2003-03-06	2004-09-23	Rina-Netzwerk Rna Technologien Gmbh	Verwendung eines trizyklischen Antidepressivums zur Förderung der Endozytose
US7476729B2 (en)	2003-10-24	2009-01-13	Institut Curie	Dbait and uses thereof
EP1526177A1 (en) *	2003-10-24	2005-04-27	Institut Curie	Nucleic acids useful for triggering tumor cell lethality
US20060051405A1 (en)	2004-07-19	2006-03-09	Protiva Biotherapeutics, Inc.	Compositions for the delivery of therapeutic agents and uses thereof
WO2007040469A2 (en) *	2005-09-15	2007-04-12	Kosak Ken M	Chloroquine coupled compositions and methods for their synthesis
US20070293449A1 (en)	2006-06-20	2007-12-20	Nastech Pharmaceutical Company Inc.	Compositions and methods for delivery of double-stranded rna
WO2008022309A2 (en)	2006-08-18	2008-02-21	F. Hoffmann-La Roche Ag	Polyconjugates for in vivo delivery of polynucleotides
EP1944369A1 (en)	2007-01-12	2008-07-16	The Centre National de la Recherche Scientifique	Dbait and its standalone uses thereof
JPWO2009063998A1 (ja)	2007-11-14	2011-03-31	株式会社リボミック	疎水性物質付加核酸及びその使用
CA2721183C (en)	2008-04-11	2019-07-16	Alnylam Pharmaceuticals, Inc.	Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
BRPI0823234A2 (pt)	2008-11-07	2019-09-24	Childrens Hospital Med Ct	nanovesícula para liberação de um agente para uma membrana biológica e processo para direcionar um agente para uma membrana de uma célula ou um tecido.
WO2010057160A1 (en)	2008-11-17	2010-05-20	Enzon Pharmaceuticals, Inc.	Releasable fusogenic lipids for nucleic acids delivery systems
RS57439B1 (sr) *	2010-06-22	2018-09-28	Onxeo	Optimizovani sistem sa endosomolitičkim agensima za in vivo primenu konjugata nukleinskih kiselina
EP2527440A1 (en) *	2011-05-27	2012-11-28	Institut Curie	Cancer treatment by combining DNA molecules mimicking double strand breaks with hyperthermia

2011
- 2011-06-21 RS RS20180764A patent/RS57439B1/sr unknown
- 2011-06-21 ES ES18167760T patent/ES2784793T3/es active Active
- 2011-06-21 LT LTEP16183451.0T patent/LT3135301T/lt unknown
- 2011-06-21 JP JP2013515845A patent/JP5860874B2/ja active Active
- 2011-06-21 HU HUE16183451A patent/HUE037926T2/hu unknown
- 2011-06-21 PL PL16183451T patent/PL3135301T3/pl unknown
- 2011-06-21 CA CA2802463A patent/CA2802463C/en active Active
- 2011-06-21 PT PT161834510T patent/PT3135301T/pt unknown
- 2011-06-21 TR TR2018/07294T patent/TR201807294T4/tr unknown
- 2011-06-21 SI SI201131507T patent/SI3135301T1/en unknown
- 2011-06-21 DK DK16183451.0T patent/DK3135301T3/en active
- 2011-06-21 EA EA201690782A patent/EA032867B9/ru not_active IP Right Cessation
- 2011-06-21 US US13/703,965 patent/US9205099B2/en not_active Expired - Fee Related
- 2011-06-21 DK DK18167760.0T patent/DK3372248T3/da active
- 2011-06-21 CN CN201510086529.4A patent/CN104788523B/zh active Active
- 2011-06-21 CN CN201180031310.4A patent/CN103025356B/zh active Active
- 2011-06-21 WO PCT/EP2011/060280 patent/WO2011161075A1/en active Application Filing
- 2011-06-21 EP EP11727679.0A patent/EP2585113A1/en not_active Withdrawn
- 2011-06-21 EA EA201300039A patent/EA023927B1/ru not_active IP Right Cessation
- 2011-06-21 ES ES16183451.0T patent/ES2674412T3/es active Active
- 2011-06-21 EP EP16183451.0A patent/EP3135301B1/en active Active
- 2011-06-21 EP EP18167760.0A patent/EP3372248B1/en active Active
- 2011-06-21 AU AU2011269041A patent/AU2011269041B2/en active Active
- 2011-06-21 EP EP20158381.2A patent/EP3689381A1/en active Pending
2012
- 2012-12-06 IL IL223467A patent/IL223467A/en active IP Right Grant
2015
- 2015-10-27 US US14/923,482 patent/US9428538B2/en active Active
2016
- 2016-08-10 US US15/232,844 patent/US9687557B2/en active Active
2017
- 2017-05-11 IL IL252241A patent/IL252241A0/en unknown
- 2017-06-26 US US15/632,951 patent/US10363317B2/en active Active
2018
- 2018-06-15 HR HRP20180934TT patent/HRP20180934T1/hr unknown
- 2018-06-27 CY CY20181100665T patent/CY1120560T1/el unknown
2019
- 2019-07-01 US US16/458,214 patent/US10765758B2/en active Active

Also Published As

Publication number	Publication date
TR201807294T4 (tr)	2018-06-21
IL223467A (en)	2017-09-28
US10765758B2 (en)	2020-09-08
DK3372248T3 (da)	2020-04-06
JP2013534521A (ja)	2013-09-05
PT3135301T (pt)	2018-07-16
EP2585113A1 (en)	2013-05-01
US20160339107A1 (en)	2016-11-24
CN103025356A (zh)	2013-04-03
AU2011269041B2 (en)	2015-05-07
ES2784793T3 (es)	2020-09-30
EP3135301A1 (en)	2017-03-01
CY1120560T1 (el)	2019-07-10
US10363317B2 (en)	2019-07-30
CA2802463C (en)	2019-02-26
CN104788523B (zh)	2017-09-08
DK3135301T3 (en)	2018-06-25
US9205099B2 (en)	2015-12-08
EP3135301B1 (en)	2018-05-02
JP5860874B2 (ja)	2016-02-16
ES2674412T3 (es)	2018-06-29
EA032867B1 (ru)	2019-07-31
EP3689381A1 (en)	2020-08-05
EA201690782A1 (ru)	2016-08-31
EA032867B9 (ru)	2020-01-22
US20170298089A1 (en)	2017-10-19
US20190314511A1 (en)	2019-10-17
CA2802463A1 (en)	2011-12-29
RS57439B1 (sr)	2018-09-28
US20160046662A1 (en)	2016-02-18
WO2011161075A1 (en)	2011-12-29
PL3135301T3 (pl)	2018-11-30
AU2011269041A1 (en)	2013-01-31
US20130131155A1 (en)	2013-05-23
SI3135301T1 (en)	2018-08-31
HUE037926T2 (hu)	2018-09-28
EA023927B1 (ru)	2016-07-29
US9687557B2 (en)	2017-06-27
IL252241A0 (en)	2017-08-31
CN103025356B (zh)	2015-02-18
EA201300039A1 (ru)	2013-05-30
CN104788523A (zh)	2015-07-22
EP3372248A1 (en)	2018-09-12
EP3372248B1 (en)	2020-03-11
HRP20180934T1 (hr)	2018-10-05
AU2011269041A2 (en)	2013-07-11
US9428538B2 (en)	2016-08-30

Publication	Publication Date	Title
HRP20180934T1 (hr)	2018-10-05	Optimizirani sustav unosa in vivo s endosomolitičkim sredstvima za konjugate nukleinskih kiselina
HK1252488A1 (zh)	2019-05-24	用於核酸遞送的組合物
ZA201302900B (en)	2014-07-25	Peptide-based in vivo sirna delivery system
EP2612917A4 (en)	2014-12-31	ANTISENSE NUCLEIC ACID
GB0903810D0 (en)	2009-04-22	Delivery system
EP2523606C0 (en)	2024-04-17	TRANSCORPOREAL DELIVERY SYSTEM
EP2493547A4 (en)	2013-06-19	EXTERNAL MAGNETIC FORCE FOR TARGETED CELLULAR SUPPORT WITH REINFORCED CELL RETENTION
EP2624798A4 (en)	2014-03-26	ARTICLE COMPRISING A BENEFICIAL AGENT DISTRIBUTION SYSTEM FOR HEALTH
PL2301234T3 (pl)	2018-10-31	Pobieranie opłat za dostarczanie krótkich wiadomości
IL208386A0 (en)	2010-12-30	Lipid-oil-water nanoemulsion delivery system for microtubule-interacting agents
EP2362909A4 (en)	2012-10-10	MAMMALIAN GENES INVOLVED IN INFECTION
IL226170A0 (en)	2013-07-31	Compositions and methods for delivery of nucleic acids based on nanopolymers
EP2451976A4 (en)	2013-05-29	NANO-BIOSENSORS WITH NUCLEIC ACIDS
EP2542564A4 (en)	2014-05-07	SYSTEM FOR TAXED RELEASE
EP2618753A4 (en)	2014-11-19	FUSION CAGE WITH A COMBINED SYSTEM FOR DELIVERY OF BIOLOGICAL AGENTS
GB2496849B (en)	2016-06-08	Improved DNA plasmid system
EP2622102A4 (en)	2014-03-12	IN VIVO RAPPORTEUR SYSTEM
GB0817486D0 (en)	2008-10-29	Delivery system
GB201000767D0 (en)	2010-03-03	Gene targeting in animals
GB0901248D0 (en)	2009-03-11	Gene targeting in animals
GB0911862D0 (en)	2009-08-19	RNA delivery vehicles
GB0903808D0 (en)	2009-04-22	Delivery system
GB2495650B (en)	2015-12-02	Liquid delivery system
GB0901961D0 (en)	2009-03-11	Delivery cart
GB201100873D0 (en)	2011-03-02	Gene targeting in animals